Terren Peizer founded Hythiam in 2003. Recognizing that advances in scientific research definitively established alcohol and drug addiction as physiological chronic diseases — not psychological, sociological or personality disorders — Peizer launched Hythiam.
Prior to forming Hythiam, Peizer founded and served as Chairman and CEO of Clearant, Inc., a biotechnology company that is a leader in pathogen inactivation solutions. Peizer has served as President and Vice Chairman of Hollis-Eden Pharmaceuticals and Chairman of the Board of Cray, Inc. — the supercomputing industry leader. He remains the largest beneficial shareholder of Cray, Inc. He also has been among the largest beneficial shareholders and senior executives at several other technology and biotechnology companies.
Peizer has assisted companies with assembling management teams, boards of directors and scientific advisory boards, and formulating business and financial strategies — including investor and public relations and capital formation. Peizer has a background in venture capital, mergers and acquisitions, investing, and corporate finance. He held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert.
Anthony M. LaMacchia
Senior Executive Vice President
Anthony LaMacchia has more than 26 years of experience in the healthcare industry. Most recently, he was the Business Development Principal of GME Solutions, a healthcare financial consulting company. LaMacchia has held various executive management positions including Director, President, and CEO of Response Oncology, Inc., and Executive Vice President and COO of Salick Health Care, Inc., a wholly owned subsidiary of Astra Zeneca PLC. LaMacchia also held positions of increasing responsibility with Blue Cross of California, Ernst & Young, and Cedars-Sinai Medical Center.
Chris Hassan
Senior Executive Vice President
Chris Hassan currently manages Hythiam’s marketing and sales operations. He has over 20 years of healthcare management experience in sales, marketing and strategic and product development positions, and he spent the last eight years focused on the treatment of substance abuse. Prior to joining Hythiam, he was responsible for the founding and development of the commercial team responsible for the U.S. launch of Suboxone™ for opiate dependence. He has also been involved with the development of novel products for the treatment of alcohol and opiate dependence at Drug Abuse Sciences, and has held management positions at Parke-Davis/Pfizer and Bayer pharmaceuticals.
Richard A. Anderson
Senior Executive Vice President
Richard Anderson has more than a decade of experience in business development, strategic planning, and financial management. He has been a Director and the Chief Financial Officer of Clearant, Inc., a biotechnology company, and served as Chief Financial Officer of Intellect Capital Group. Anderson also served as a consultant to various developmental and emerging growth companies. Anderson was with Price Waterhouse accounting firm, most recently as a Director and Founding Member of PriceWaterhouseCoopers Transaction Support Group, where he was involved in operational and financial due diligence, valuations, and structuring for technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.
Leslie F. Bell, Esq.
Leslie Bell has more than 35 years of experience in business and the practice of corporate and healthcare law. He is a senior executive of Salick Cardiovascular Centers, Inc. He has served as a Director and Senior Executive of Bentley Health Care, Inc., a developer and provider of disease-state outpatient healthcare facilities and services. Bell also was Co-Chairman and Co-Chief Executive Officer of Tractus Medical, Inc., a provider of patented relocatable ambulatory surgical center/operating rooms, which he co-founded in January 2002. From its inception in 1983 through several public offerings, and until its sale completed in 1997, he served as a Director, President, and CFO of Salick Health Care, Inc., which created and pioneered the development and operation of a national network of comprehensive outpatient cancer centers providing a full image of detection, diagnosis, and treatment. The Company also operated numerous end-stage renal disease (kidney dialysis) treatment centers and a clinical research organization engaging in pharmaceutical and clinical treatment trials.
Bell has also served as a Director of YES Clothing Co. from 1990 to 1995. He was a Deputy Attorney General of the State of California from 1964 to 1966, when he joined the law firm that became Katz, Hoyt & Bell, where he served as Managing Partner from 1975 until 1983. Bell attended University of Illinois, received a J.D. (with honors) from University of Arizona College of Law, and is a member of the University of Arizona College of Law Board of Overseers and the Dean's Economic Council.
Ivan M. Lieberburg, Ph.D., M.D.
Dr. Ivan Lieberburg is currently Executive Vice President, Chief Medical Officer at Elan Company, plc (formerly Athena Neurosciences, Inc.), a worldwide biopharmaceutical company listed on the New York Stock Exchange, where he has held a number of positions over the last 18 years, most recently Senior Vice President of Research.
Prior to joining Elan in 1987, Dr. Lieberburg held faculty positions at Albert Einstein School of Medicine and Mt. Sinai School of Medicine. Dr. Lieberburg received an A.B. in Biology from Cornell University, a Ph.D. in Neurobiology from The Rockefeller University, and an M.D. from the University of Miami School of Medicine. He performed his postdoctoral research at The Rockefeller University and his medical residency and postdoctoral fellowship at the University of California, San Francisco, where he is presently a Clinical Professor of Medicine.
Dr. Lieberburg has authored over 100 scientific publications, and has been named to a number of honors including Rockefeller University Fellow, Public Health Corps Scholar, National Research Service Award, Hartford Foundation Scholar, and McKnight Fellow. He is board-certified in internal medicine and endocrinology/metabolism. Dr. Lieberburg is a director of Neuromolecular Pharmaceuticals, and he sits on the scientific advisory boards of Health Care Ventures, Flagship Ventures, NewcoGen, Neuromolecular Pharmaceuticals, CovX, Hythiam, and the Keystone Symposium.
Marc G. Cummins
Marc Cummins is a Managing Partner of Catterton Partners, a private equity investor in consumer products and service companies with over $1 billion of assets under management. Prior to joining Catterton in 1988, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was Managing Director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings. He currently serves on the boards of several private companies including Case Logic Inc., Floorgraphics Inc., Titan Outdoor, LLC and DoveBid, Inc. Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at the University of Pennsylvania.
Dr. Andrea Grubb Barthwell
Dr. Andrea Grubb Barthwell is the former Deputy Director for Demand Reduction of the White House Office of National Drug Control Policy (ONDCP). Prior to joining ONDCP, Barthwell served as President of American Society of Addiction Medicine (ASAM). She has served as President of the Encounter Medical Group in Oak Park, Illinois and as President and Executive Vice President of two major drug treatment providers in Chicago.
Before her recent government service on President Bush's sub-cabinet, she served on the National Advisory Councils of the National Institute on Drug Abuse (NIDA), on the Center for Substance Abuse Treatment and on the Drug Abuse Advisory Committee of the Food and Drug Administration (FDA). Dr. Barthwell received her Bachelor of Arts in Psychology from Wesleyan University in Connecticut and her Doctor of Medicine from University of Michigan Medical School. She did her post-graduate training at University of Chicago and Northwestern University Medical Center.
Honorable Karen Freeman-Wilson (ret.)
Judge Freeman-Wilson has previously served as Chief Executive Officer of the National Association of Drug Court Professionals (NADCP) and Executive Director of the National Drug Court Institute.
Prior to joining the NADCP, Freeman-Wilson served as Attorney General for the State of Indiana, where she served as the first Vice Chair of the Indiana Tobacco Control Board. Prior to that, she served as Presiding Judge of Gary, Indiana's Municipal Court and initiated the first drug treatment court in the State of Indiana. Before her recent government positions, she was Director of the Indiana Civil Rights Commission. Judge Freeman-Wilson received her Bachelor of Arts degree from Harvard College and her Juris Doctorate from Harvard Law School.
